BACKGROUND: Synuclein-g (SNCG) is highly expressed in advanced solid tumors, including uterine serous carcinoma (USC). The objective of the current study was to determine whether SNCG protein was associated with survival and clinical covariates using the largest existing collection of USCs from the Gynecologic Oncology Group (GOG-8023). METHODS: High-density tissue microarrays (TMAs) of tumor tissues from 313 patients with USC were stained by immunohistochemistry for SNCG, p53, p16, FOLR1, pERK, pAKT, ER, PR, and HER2/neu. Associations of SNCG and other tumor markers with overall and progression-free survival were assessed using log-rank tests and Cox proportional-hazards models, which also were adjusted for age, race, and stage. RESULTS: The overall survival at 5 years was 46% for women with high SNCG expression and 62% for those with low SNCG expression (log-rank P 5.021; hazard ratio [HR], 1.31; 95% confidence interval [CI], 0.91-1.9 in adjusted Cox model). The progression-free survival rate at 5 years was worse for women who had high SNCG expression, at 40%, compared with 56% for those who had low SNCG expression (log-rank P 5.0081; HR, 1.36; 95% CI, 0.96-1.92 in adjusted Cox model). High levels of both p53 and p16 were significantly associated with worse overall survival (p53: HR, 4.20 [95% CI, 
INTRODUCTION
Endometrial carcinoma is the most common gynecologic malignancy in the United States, with an estimated 54,870 diagnosed in 2015. 1 Despite an overall good prognosis, the survival of women with endometrial carcinoma varies dramatically, depending upon the histologic subtype. Although uterine serous carcinoma (USC) accounts for about 10% of endometrial cancers, the prognosis is substantially worse than the more common endometrioid adenocarcinoma, with frequent recurrences and high mortality rates. 2, 3 Active treatment modalities remain elusive, because neither its pathogenesis nor the nature of its aggressive behavior and chemoresistance is well understood.
It has been demonstrated that synuclein-c (SNCG) is overexpressed in USC. [4] [5] [6] SNCG is a member of the synuclein family of proteins, which are small, soluble, highly conserved neuronal proteins implicated in both neurodegenerative diseases and cancer. SNCG overexpression occurs in multiple cancers, including colon, gastric, pancreatic, ovarian, and lung cancers. [7] [8] [9] [10] [11] [12] [13] [14] SNCG was first termed breast cancer-specific gene 1 (BCSG1), because it was correlated with a poor prognosis and advanced stage in breast cancer. 7, 10 The mechanisms by which SNCG promotes advanced disease and chemoresistance reportedly involve modulating the mitogenactivated kinases (MAPKs), extracellular signal-regulated protein kinases 1 and 2 (ERK1/ERK2), and c-Jun N-terminal kinase 1 (JNK1). 15 In addition, it has been demonstrated that SNCG interferes with paclitaxel-induced mitotic arrest by interacting with the mitotic checkpoint kinase BUB1B (budding uninhibited by benzimidazoles 1, beta), resulting in the inability of preventing cells with misaligned chromosomes from exiting mitosis. 16 Additional studies are necessary to define the role of SNCG in USC.
We first identified SNCG expression specifically in USC through a pathway-focused expression array, followed by correlative analysis of SNCG expression with survival in 20 patients with USC. 6 Although statistical significance was not reached because of a limited sample size, a trend toward an association of SNCG with decreased progression-free survival was evident. In a larger study evaluating 279 endometrial carcinomas with various histologies, of which 46 were USC, SNCG expression was positive in tumors from patients who had worse overall outcomes, especially those with clear cell, serous, and carcinosarcoma histologies. 5 These data strongly suggest that SNCG may be a prognostic biomarker for USC.
The objective of this study was to determine whether SNCG protein was associated with clinicopathologic variables and patient outcomes in a sufficiently large collection of USC tumors. The associations of SNCG and other tumor markers, including p53 (tumor protein 53) and p16 (cyclin-dependent kinase inhibitor 2A), with multiple clinical parameters, including survival, were determined. To our knowledge, this is the largest collection of USCs to date, representing 313 women with USC obtained from the Gynecologic Oncology Group (GOG) through its clinical trial programs.
MATERIALS AND METHODS

Patient Selection
In the GOG-8023 study, women with USC who were eligible for and enrolled in GOG-0210 (a molecular staging study 17 , had consented for future research, and had histologically confirmed USC were included for tumor microarray (TMA) construction. If there was insufficient tissue submitted on GOG-0210, then tissue collected on another study, GOG-0136 (a specimen banking study), was used. The diagnosis of USC was reviewed for each case by the GOG Pathology Committee. Research specimens were reviewed by the study pathologists to confirm that primary tumor consisted of at least 90% serous carcinoma. The presence of any nonserous histologic components was noted, but the histology in all cases was considered consistent with USC overall.
Clinical Data
Overall survival was defined as the observed length of life from study entry to death. Progression was defined as increasing clinical, radiologic, or histologic evidence of disease after study entry; and progression-free survival was defined as the time from study entry to the date of disease recurrence, progression, or death (whichever occurred first). Lengths of follow-up from study entry until the date of last contact for women without death or progression were treated as censored observations for overall survival and progression-free survival analyses, respectively. Types of adjuvant therapy were recorded using the following general terms: chemotherapy, radiation therapy, chemoradiation, hormonal therapy, other treatment regimen, or none. Additional details were recorded when appropriate. Other variables examined were age (at study entry); race; International Federation of Gynecology and Obstetrics 1988 surgical stage (I-II vs III-IV); presence or absence of lymphovascular space invasion; depth of myometrial invasion (none, < 50%, 50%, serosal involvement); involvement of pelvic and/or para-aortic lymph nodes; and presence or absence of pelvic disease, abdominal disease, peritoneal disease, and distant disease.
TMA
A high-density TMA was created by the GOG Tissue Bank, which consisted of four 10 3 10 grids of 0.6-mm tissue cores positioned as 4 quadrants on 1 microarray. Each 10 3 10 grid included 90 randomly positioned USC patient tissues as well as 10 control tissues (5 normal human tissues, 5 human cancer tissues). Of the 90 tumors, 47 were represented in duplicate for a total of 313 patient tumors represented in the TMA. There were 4 replicate TMAs.
Immunohistochemistry
Immunohistochemical (IHC) analyses were performed for the following biomarkers: SNCG, estrogen receptor (ER), progesterone receptor (PR), p53, human epidermal growth factor type 2 receptor (HER2/neu), folate receptor 1 (FOLR1), p16, phosphorylated protein kinase B (pAKT), and phosphorylated extracellular signalregulated kinase (pERK). Immunostains for all except HER2/neu were performed at the GOG Tissue Bank housed at the Biopathology Center, which is part of the Research Institute at Nationwide Children's Hospital, under the supervision of Dr. Nilsa Ramirez. Immunostaining for HER2/neu was performed at the Pathology Core Facility of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University under the supervision of Dr. Jian-Jun Wei. The details for each antibody are summarized in Table 1 . All antibodies were tested on negative and positive control tissues provided by both the Northwestern Human Pathology Core and the GOG Tissue Bank.
To validate the immunostains, each biomarker was also assessed in conventional blocks from 10% of the cases to confirm that the expression of each biomarker in the 0.6-mm cores was representative of the expression in full tissue sections. A semiquantitative immunoreactivity for all markers was scored by 2 pathologists. All immunostains except HER2/neu were scored by intensity (11, 21, or 31) and by the percentage of stained tumor cells (0%, 1%-10%, 11%-20%, 21%-30%, 31%-40%, 41%-50%, 51%-60%, 61%-70%, 71%-80%, 81%-90%, 91%-100%). HER2/neu was scored as 0, 11, 21, or 3 1 based on the 2007 scoring criteria established for breast cancer. 18 Marker definitions for each of the included biomarkers are delineated in Table 2 . For SNCG, intensity and percentage scores were initially combined into overall scores of low, medium, and high. The low category was defined as either no staining (0%) or 1 1 intensity with 20% of cell stained. The medium category was defined as 1 1 intensity with > 20% of cells stained or 2 1 to 3 1 intensity with from 1% to 50% of cells stained. The high category was defined as 2 1 to 3 1 intensity with > 50% of cells stained. For p53, the high category was defined as >30% with any intensity or 0% labeling index (dead negative, indicative of null mutation).
The final immunoscores obtained for SNCG, p53, and pAKT were based on the most frequent scores from quadruplicate tissue cores. When this algorithm was inconclusive, the raw data were reviewed, and a representative summary score was determined. For the remaining markers, only 1 TMA reading was performed. Upon initial analysis for SNCG staining, the survival curves were similar for the medium and high groups. Thus, these categories were combined into a single high category, resulting in 2 SNCG expression groups (low and high) that were subsequently used for analysis.
Power Considerations
The study was originally designed to include 3 SNCG expression groups (low, medium, and high). Across a range of SNCG expression group distributions, a total sample size of 300 afforded 80% power, with 5% probability of a 2-sided Type I error and 10% loss-to-follow-up, to detect overall survival hazard ratios (HRs) from 0.46 to 0.56 for low versus medium SNCG expression and from 1.63 to 1.81 for high versus medium SNCG expression, depending on the size of the low, medium, and high groups. 19 A target sample size of 360 for TMA construction was set to allow for potential core loss. In our analyses, because of the similarity of effect estimates, the medium and high expression groups were combined for analysis. In post hoc power calculations, our observed sample sizes in the SNCG expression groups yielded 80% power with 5% probability of a 2-sided Type I error to detect an HR of roughly 1.62 for the high versus low SNCG expression groups.
Statistical Analysis
Clinical and biomarker variables were summarized using means and standard deviations for age and tables of frequencies and counts for all other categorical variables. SNCG expression was the primary predictor of interest. Analyses were initially conducted using 3 SNCG expression categories, as planned. Few differences in survival distributions and hazard functions were observed in all analyses for the original medium and high expression groups; hence, these 2 categories were combined, and 2 SNCG expression groups (high vs low) were used for final analyses (Table 3) . Secondary predictors of interest were expression of FOLR1, pERK, pAKT, p53, p16, ER, and PR (all high vs low) as well as HER2/neu expression (positive, negative, or equivocal). The primary outcome was overall survival (time in months), and the secondary outcome was progression-free survival (time in months). Age, race, surgical stage, presence of lymph-vascular space invasion, depth of myometrial invasion, pelvic and/ or para-aortic lymph node involvement, pelvic disease, abdominal disease, peritoneal disease, distant disease, and adjuvant treatment were all summarized to describe the patient population and were examined for associations with SNCG expression using a t test for age and a chisquare or Fisher exact test for categorical variables. Clinical characteristics that demonstrated an association with SNCG expression groups at P < .05 were included in Cox proportional hazards models to assess potential confounding in SNCG associations with time-to-event outcomes.
Kaplan-Meier curves for overall and progressionfree survival were generated for both SNCG groups. Logrank tests were used to assess differences between the curves. Cox proportional hazards models were used to estimate HRs, and adjustments for age, race, and disease stage were examined in Cox models. The same process was used for all tumor markers of secondary interest. HRs were estimated in multiple marker models for SNCG and p16 and for SNCG and p53.
RESULTS
SNCG in USC
USC tumors from patients enrolled on GOG-0210 were collected, and TMAs were constructed by the GOG Tissue Bank (available at: http://www.nationwidechildrens. org/biopathology-center-collaborations). Clinical data and adequate tissue specimens were available for analysis from 313 patients. Immunostaining for SNCG revealed a variable extent (focal/patchy to extensive/diffuse) and intensity of staining, which was localized predominantly to the cytoplasm of tumor cells, with occasional nuclear staining (Fig. 1) . The staining was categorized as high or low based on the intensity of staining and the percentage of cells stained (low, 0-1 intensity with 20% of tumor cells stained; high, 2-3 intensity or > 20% of tumor cells stained) ( Table 2 ). High expression of SNCG was observed in 61.8% of specimens (Table 3) . There was a statistically significance difference in the mean age at diagnosis, which was 67.2 years and 69.8 years for the low and high SNCG expression groups, respectively (P 5 .01) ( Table 4) . Surgical stage; histologic heterogeneity; the presence of lymphovascular space invasion; the depth of myometrial invasion; pelvic and para-aortic lymph node metastasis; the presence of pelvic, abdominal, peritoneal, or distant disease; and the type of adjuvant treatments received were similar across the SNCG groups. Although no differences in SNCG expression were observed according to race or stage, these covariates were included along with age in adjusted models because of their known associations with overall survival. In unadjusted analyses, overall survival was statistically significantly worse for women who had tumors that demonstrated high SNCG expression (log-rank test; P 5 .021) (Fig. 2, Table 5 ). At 5 years, the overall survival estimates were 62% for the low SNCG expression group and 46% for the high SNCG expression group. The association between SNCG and overall survival was attenuated in adjusted Cox models, with an HR of 1.31 (95% confidence interval [CI], 0.91-1.9; P 5 .15) after adjusting for age, race, and stage. Progression-free survival was Original Article also statistically significantly lower for women who had tumors with high SNCG expression in unadjusted analyses (log-rank test; P 5 .0081) (Fig. 2 , Table 5 ). At 3 years, 63% of women who had tumors with low SNCG expression were progression free versus 47% of those who had tumors with high SNCG expression. This also was observed at 5 years, with progression-free survival rates of 56% and 40% for the low and high SNCG expression groups, respectively. A Cox model HR adjusted for age, race, and stage favored low SNCG expression (HR for low vs high expression, 1.36; 95% CI, 0.96-1.92; P 5 .086). The Kaplan-Meier plots in Figure 2 illustrate lower survival for the high SNCG group compared with the low SNCG expression group. The trends were similar when survival was examined separately for white and black (Supporting Fig. 1 ; see online supporting information).
Association of Other Tumor Markers in USC
Next, we sought to determine the expression patterns of other known molecular markers in endometrial cancer and their associations with progression and survival outcomes. The TMAs were stained for p53, p16, FOLR1, pERK, pAKT, PR, ER, and HER2/neu, and their expression levels were scored as either high or low (Table 3 , Supporting Figs. 2 and 3; see online supporting information). Greater than 50% of patients had high immunoreactivity for SNCG, p53, p16, and FOLR1, as summarized in Table 3 . HER2/neu was positive in only 2.2% of USC samples and was negative in >95%. Less than 20% of samples exhibited high immunoreactivity for pERK and pAKT, whereas the majority (>80%) had low levels. Immunoreactivity for both ER and PR was low in more than 50% of samples. Among the markers tested, only p53 and p16 were significantly associated with unfavorable clinical outcomes. Women who had tumors that demonstrated high p53 expression had worse overall survival (HR, 4.2; 95% CI, 1.54-11.45; P 5 .005) and disease progression (HR, 2.16; 95% CI, 1.09-4.27; P 5 .027) ( Table 6 ). Trends were also evident for those who had tumors with high p16 expression associated with worse overall survival (HR, 1.95; 95% CI, 1.01-3.75; P 5 .046) and progression-free survival (HR, 1.53; 95% CI, 0.87-2.69; P 5 .14) ( Table  6 ). Expression levels of p16 and p53 were associated, with approximately 92% of tumors that had high p53 expression also demonstrating high p16 expression (P < .0001). Cox models using multiple markers were also examined to determine whether the association of SNCG with overall and progression-free survival was independent of p53 and p16 associations. In Cox models that included SNCG and p53 as well as age, race, and stage, associations of SNCG with the outcomes were attenuated and were no longer statistically significant, with an HR of 1.19 (95% CI, 0.81-1.73; P 5 .37) for overall survival and 1.27 (95% CI, 0.89-1.81; P 5 .19) for progression-free survival. When SNCG and p16 were included in a model together, associations with overall and progression-free survival were attenuated and were not statistically significant for either marker. Nevertheless, > 90% of tumors with high SNCG expression also had high p53 and/or p16 expression (Table 7 ). The expression of FOLR1, pERK, pAKT, PR, and ER and the HRs for these markers were not statistically significant (Table 8) .
DISCUSSION
The incidence of USC is rare, accounting for only 10% of newly diagnosed endometrial cancers. However, USC is one of the most aggressive tumors of the endometrium, with high recurrence and associated mortality rates. 2, 3 Active treatment modalities remain elusive, because neither its pathogenesis nor its chemoresistance is well understood. From one-third to one-half of USC tumors are admixed with other histologic subtypes, 20 although recent literature based on data from The Cancer Genome Atlas indicates that the morphologic reproducibility of carcinomas with mixed or ambiguous histology is poor, and polymerase e (POLE)-ultramutated endometrioid carcinomas in particular may be morphologically misdiagnosed as USC. 21, 22 Notwithstanding these newer data, however, morphology-based studies have indicated that, even when the USC component contributes as little as 10% to the tumor, its behavior can resemble pure serous carcinoma. 23 A significant limitation to studying USC is the small number of patients at any one institution. The GOG, with the cooperation of multiple centers, has collected thousands of endometrial cancer samples through various clinical trial protocols. Specifically, the USC tumor specimens used in the current study were collected and banked as part of the GOG-0210 and GOG-0136 clinical trials. Consequently, 313 patients with USC who had adequate tumors represented on the TMA and detailed clinical information were available for this study, representing the largest collection of USC tumors with corresponding clinical information available for investigation to date. The statistical study design planned the sample size to have 80% statistical power, with 5% probability of a 2-sided Type I error and 10% loss to follow-up, to detect HRs of 0.46 to 0.56 for low versus medium SNCG expression and 1.63 to 1.81 for high versus medium SNCG expression in the original 3-group design. The results revealed a statistically significant association between SNCG expression and both overall and progression-free survival in univariate analyses. In addition, given the size of this cohort, standardized criteria for a relatively reliable cutoff score for SNCG to allow for interpretation of immunoreactivity for SNCG could be established. Consistent with a recent study, 4 scoring for low and high SNCG expression is a reproducible approach to interpreting IHC scores for SNCG in USC. Further validation of technical methodology and interpretation criteria will be needed before the widespread adoption of SNCG IHC staining as a diagnostic or prognostic marker.
According to our study, the survival of women who had tumors with high SNCG expression was worse, despite the absence of a statistically significant association Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SNCG, synuclein-g. a OS and PFS estimates were evaluated based on high and low SNCG expression levels using the log-rank test. b HRs were calculated by comparing high versus low SNCG expression and are adjusted for age, race, and stage with 95% CIs and P values.
between SNCG expression and certain clinical parameters at the time of USC diagnosis, including stage, depth of myometrial invasion, lymphovascular space invasion, and lymph node metastasis. Unadjusted analyses demonstrated a statistically significant association between SNCG expression and both overall and progression-free survival, although the associations were attenuated after adjustment for age, race, and stage. Additional investigations with larger samples may clarify these associations, because the observed HRs for both time-to-event outcomes in these data were slightly lower than the HRs we were adequately powered to detect. USC is an aggressive malignancy, with early intra-abdominal and retroperitoneal spread even in the absence of traditional risk factors, such as deep myometrial invasion, tumor size, and lymphovascular space invasion. 3 Thus SNCG may be associated with mechanisms related to this unique spread pattern. However, there is still much to be learned regarding the genes and pathways that permit metastasis preferentially into the abdominal and peritoneal cavities. Molecular studies have suggested the involvement of SNCG in chemoresistance. It was demonstrated that SNCG binds to a spindle checkpoint kinase, BUB1B, thereby inducing a structural change in BUB1B. This inhibited its kinase activity and attenuated its interaction with other key checkpoint proteins, such as cell-division cycle protein 20 (Cdc20), compromising the spindle assembly checkpoint. 16, 24, 25 The lack of checkpoint function would allow cells to override G2/M arrest with aneuploidy proliferation to perpetuate genomic instability. By targeting SNCG with a specific peptide, sensitivity to paclitaxel was enhanced. 26 The association of SNCG with clinical chemoresistance was not assessed in the current study because of insufficient information, and it remains an unanswered question. Most women in this study received some form of adjuvant therapy, and the distribution of chemotherapy, pelvic radiotherapy, or both was similar in both the low and high SNCG expression groups. The use of SNCG as a marker for chemoresistance is a plausible option that should be explored.
We did examine the association of SNCG with other tumor markers in this study. Among the markers tested, only p53 and p16 were associated with both overall and progression-free survival. To our knowledge, this is the largest cohort to demonstrate the association of p53 or p16 with survival in patients with USC, providing evidence of the prognostic potential of these 2 markers. Only one other study demonstrated a significant association of p53 with worse survival in 34 patients with USC, 27 whereas association studies of p16 and survival in USC have not been reported, underscoring the relevance of our study of 313 women with USC. High versus low expression of the other markers (pAKT, pERK, ER, PR, and FOLR1) was not significantly associated with survival. The expression of these markers has been studied extensively in endometrioid carcinoma, but their role in USC is less understood. ER has been associated with SNCG, which increases the transcriptional activity of ER to mediate estrogen-driven proliferation in the mammary gland. [28] [29] [30] SNCG can stimulate membrane-initiated estrogen signaling to stimulate growth and promote tamoxifen resistance in breast cancer cells. 30 The data regarding whether ER contributes to the aggressive nature of USC are sparse, although USC is distinct from endometrioid adenocarcinoma with regard to hormone dependence. An analysis of 71 women with USC in Japan demonstrated an overall and progression-free survival advantage with positive hormone receptor status. 31 However, in our study, neither ER nor PR was associated with survival outcomes. In our study, we grouped IHC staining for ER and PR according to high versus low expression, whereas the Japanese study compared positive hormone (either ER or PR) expression versus negative hormone expression (for either ER or PR). Nevertheless, in our study, 40% and 36% of USC tumors expressed high levels of ER and PR, respectively. It remains to be determined whether ER and PR actively influence the behavior of USC. Signaling pathways, including AKT and MAPK, have been implicated in driving metastasis and chemoresistance in tumors [32] [33] [34] [35] [36] and thus were markers of interest in the current study. Moreover, it has been demonstrated that SNCG maintains pAKT and mechanistic target of rapamycin (mTOR) activities that protect cells from the cytotoxicity related to disabling heat-shock protein 90 (Hsp90). 37 Similarly, SNCG protects HER2/neu function, rendering it resistant to Hsp90-mediated toxicity. 38 In the current study, although none of these markers were independently associated with survival, it is possible that they may play a role in resistance to treatments.
HER2/neu is amplified in a wide range of tumors, from 10% to 65%, depending on the study. [39] [40] [41] [42] In our study, staining for HER2/neu was low. It is noteworthy that we used breast cancer criteria for scoring HER2/neu expression in USC, because specific criteria for scoring HER2/neu in USC have not yet been established. One study reported that screening for HER2/neu with IHC overestimated the number of tumors with HER2/neu gene amplification, because there was significant discordance between IHC and in situ hybridization results. 43 In addition, the clinical relevance of HER2/neu in USC is not entirely clear: Some studies have reported an association between HER2/neu and poor overall survival in patients with Type II endometrial cancer (and specifically USC), 39, 44 whereas others have demonstrated no association with survival. 41 We could not conduct a survival analysis for HER2/neu expression in our study because of the low numbers of tumors that exhibited staining. Additional testing with in situ hybridization staining along with IHC would be a more accurate measure of the positive cases.
In summary, this study demonstrated a statistically significant association of SNCG with poor survival outcomes among patients with USC in unadjusted analyses, although some attenuation of the association was observed after adjustment for age, race, and stage. Levels of p53 and p16 also were associated significantly with worse survival. In analyses of multiple markers, SNCG did not demonstrate statistically significant associations after adjustment for p53 or p16; hence, these data do not support SNCG as an independent predictor of survival outcomes. However, the association of SNCG with markers of advanced disease merits further investigation of its role in USC biology or as a predictive biomarker. Unlike p53 or p16, SNCG has been detected in sera from patients who harbor tumors. 9, 14, 45, 46 A serum biomarker, along with other tumor markers, could aid in earlier diagnosis or detecting recurrence. In addition, the role of SNCG in predicting chemoresistance remains to be studied. Finally, this study reports the largest collection of patients with USC who had clinical information indicating that SNCG, p53, and p16 are associated with worse survival outcomes. This resource can be used to study other promising tumor marker candidates for this rare uterine cancer.
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